Warchi Palisade Bio ( NASDAQ: PALI ) on Tuesday said the Canadian Intellectual Property Office (CIPO) issued a notice of allowance for a patent application titled “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors .” The patent covers the composition of PALI-2108, the company’s orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by ulcerative colitis. Source: Press Release More on Palisade Bio Palisade Bio GAAP EPS of -$4.
59 Palisade Bio stock rallies 50% premarket on colitis drug update Seeking Alpha’s Quant Rating on Palisade Bio Historical earnings data for Palisade Bio Financial information for Palisade Bio.
